Goldman Sachs’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $85.6M | Sell |
|
|||||
|
2025
Q2 | $86.2M | Sell |
|
|||||
|
2025
Q1 | $81.6M | Sell |
|
|||||
|
2024
Q4 | $134M | Sell |
|
|||||
|
2024
Q3 | $117M | Sell |
|
|||||
|
2024
Q2 | $156M | Buy |
|
|||||
|
2024
Q1 | $107M | Buy |
|
|||||
|
2023
Q4 | $91.1M | Sell |
|
|||||
|
2023
Q3 | $88.5M | Sell |
|
|||||
|
2023
Q2 | $77.8M | Sell |
|
|||||
|
2023
Q1 | $98.2M | Sell |
|
|||||
|
2022
Q4 | $159M | Buy |
|
|||||
|
2022
Q3 | $128M | Sell |
|
|||||
|
2022
Q2 | $122M | Sell |
|
|||||
|
2022
Q1 | $140M | Sell |
|
|||||
|
2021
Q4 | $130M | Buy |
|
|||||
|
2021
Q3 | $138M | Buy |
|
|||||
|
2021
Q2 | $139M | Buy |
|
|||||
|
2021
Q1 | $137M | Buy |
|
|||||
|
2020
Q4 | $117M | Buy |
|
|||||
|
2020
Q3 | $85.5M | Sell |
|
|||||
|
2020
Q2 | $115M | Buy |
|
|||||
|
2020
Q1 | $78.1M | Buy |
|
|||||
|
2019
Q4 | $70.9M | Sell |
|
|||||
|
2019
Q3 | $60.2M | Buy |
|
|||||
|
2019
Q2 | $48.3M | Buy |
|
|||||
|
2019
Q1 | $47.1M | Sell |
|
|||||
|
2018
Q4 | $41.3M | Sell |
|
|||||
|
2018
Q3 | $161M | Sell |
|
|||||
|
2018
Q2 | $141M | Sell |
|
|||||
|
2018
Q1 | $148M | Sell |
|
|||||
|
2017
Q4 | $166M | Sell |
|
|||||
|
2017
Q3 | $149M | Sell |
|
|||||
|
2017
Q2 | $123M | Buy |
|
|||||
|
2017
Q1 | $75.5M | Buy |
|
|||||
|
2016
Q4 | $28.9M | Buy |
|
|||||
|
2016
Q3 | $36.6M | Buy |
|
|||||
|
2016
Q2 | $29.1M | Sell |
|
|||||
|
2016
Q1 | $31M | Buy |
|
|||||
|
2015
Q4 | $11.8M | Sell |
|
|||||
|
2015
Q3 | $12.8M | Buy |
|
|||||
|
2015
Q2 | $11.2M | Sell |
|
|||||
|
2015
Q1 | $22.6M | Buy |
|
|||||
|
2014
Q4 | $9.24M | Sell |
|
|||||
|
2014
Q3 | $9.68M | Sell |
|
|||||
|
2014
Q2 | $9.23M | Sell |
|
|||||
|
2014
Q1 | $11.9M | Buy |
|
|||||
|
2013
Q4 | $3.92M | Sell |
|
|||||
|
2013
Q3 | $6.11M | Buy |
|
|||||
|
2013
Q2 | $4.72M | Buy |
|